Form 4: Orchestra BioMed Holdings Director Acquires and Sells Shares

Orchestra BioMed Holdings, Inc. Director John Prosper Mack reported transactions involving restricted stock units and common stock.

Summary

• John Prosper Mack, a Director at Orchestra BioMed Holdings, Inc., was awarded 34,653 Restricted Stock Units (RSUs) on June 23, 2026.
• These RSUs are contingent rights to receive one share of Common Stock each and are set to vest one year from the grant date, provided continuous service.
• On June 24, 2026, 3,510 shares of Common Stock were withheld by the Issuer to cover tax obligations related to the vesting of RSUs.
• No market sales were conducted to cover these tax withholding obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine equity awards and tax-related share withholding for a director, rather than significant new investment or divestment.

Positives

• Director received an award of restricted stock units, indicating potential future equity ownership.
• The withholding of shares for tax obligations was handled internally by the issuer, avoiding market sales.

Negatives

• A portion of the awarded shares (3,510) were used to satisfy tax withholding obligations, reducing the net shares received by the director.

Future Outlook

The RSUs awarded on June 23, 2026, will vest on the one-year anniversary of the grant date, subject to the reporting person's continuous service.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This specific filing details the award and subsequent tax-related withholding of equity for a director.

Stakeholder Impact

• Shareholders: Increased transparency into director's equity holdings and transactions.
• Director: Will receive additional shares upon vesting of RSUs, subject to continuous service and tax obligations.

Next Steps

• The RSUs are expected to vest on June 23, 2027, contingent on continued service.
• Further transactions by the director will be reported on subsequent Form 4 filings.

Key Dates

Keywords

Orchestra BioMed Holdings, OBIO, Form 4, Insider Trading, Restricted Stock Units, RSUs, Director, Securities Transaction, Tax Withholding